Interval design to identify the optimal biological dose for immunotherapy
Immunotherapeutics have revolutionized the treatment of metastatic cancers and are expected to play an increasingly prominent role in the treatment of cancer patients. Recent advances in checkpoint inhibition show promising early results in a number of malignancies, and several treatments have been...
Main Author: | Yeonhee Park |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Contemporary Clinical Trials Communications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865422001223 |
Similar Items
-
A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs
by: Chen Li, et al.
Published: (2022-12-01) -
Optimal biological dose: a systematic review in cancer phase I clinical trials
by: J. Fraisse, et al.
Published: (2021-01-01) -
Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial
by: Masahiro Kojima
Published: (2022-04-01) -
A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation
by: Jin Xu, et al.
Published: (2022-10-01) -
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
by: Christophe Maritaz, et al.
Published: (2022-01-01)